Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial.

Abstract

BACKGROUND:

To determine the safety and efficacy of different doses of tolvaptan for treating Chinese cirrhotic patients with or without hyponatraemia who still had ascites after routine therapy with diuretics.

METHODS:

In the present placebo-controlled, randomized, double-blinded, multicentre clinical trial, patients with cirrhotic ascites who failed to adequately respond to a combination of an aldosterone antagonist plus an orally administered loop diuretic were randomly placed at a 4:2:1 ratio into 3 groups [the 15 mg/day tolvaptan group (N = 301), 7.5 mg/day tolvaptan group (N = 153) and placebo group (N = 76)] for 7 days of treatment. The effects and safety were evaluated on days 4 and 7. A change in body weight from baseline on day 7 of treatment was the primary endpoint.

RESULTS:

The administration of 7.5 or 15 mg/day tolvaptan significantly decreased body weight from baseline on day 7 of treatment compared to that with placebo treatment (P = 0.026; P = 0.001). For the secondary endpoints, changes in abdominal circumference from baseline and improvements in ascites were markedly different in the treatment groups and the placebo group on day 7 (P7.5 = 0.05, P15.0 = 0.002 and P7.5 = 0.037, P15.0 = 0.003), but there was no difference between the 7.5 mg/day and 15 mg/day dosage groups. The 24-h cumulative urine volume was higher in the 7.5 mg/day and 15 mg/day tolvaptan groups than the placebo group (P = 0.002, P < 0.001) and was greater in the 15 mg/day tolvaptan group than the 7.5 mg/day tolvaptan group (P = 0.004). Sodium serum concentrations were higher in patients with hyponatraemia after tolvaptan treatment, with no significant difference between the two dosage groups. The incidence of serious adverse drug reactions was not different between the groups (P = 0.543).

CONCLUSIONS:

Tolvaptan treatment at 7.5 mg per day might be a good therapeutic choice for Chinese cirrhotic patients with ascites who did not achieve satisfactory clinical responses to previous treatment regimens with combination therapy with an aldosterone antagonist and an orally administered loop diuretic.

TRIAL REGISTRATION:

NCT01349348. Retrospectively registered May 2011.

• Authors: Jieting Tang, Yongfeng Wang, Tao Han, Qing Mao, Jun Cheng, Huiguo Ding, Jia Shang, Qin Zhang, Junqi Niu, Feng Ji, Chengwei Chen, Jidong Jia, Xiangjun Jiang, Nonghua Lv, Yueqiu Gao, Zhenghua Wang, Zhong Wei, Yingxuan Chen, Minde Zeng, Yimin Mao
• Journal: BMC gastroenterology (BMC Gastroenterol) Vol. 20 Issue 1 Pg. 391 (Nov 19 2020) ISSN: 1471-230X [Electronic] England
• PMID: 33213378 (Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Antidiuretic Hormone Receptor Antagonists
• Benzazepines
• Diuretics
• Tolvaptan

Topics

• Antidiuretic Hormone Receptor Antagonists
• Ascites (drug therapy, etiology)
• Benzazepines
• China
• Diuretics
• Humans
• Liver Cirrhosis (complications, drug therapy)
• Tolvaptan